Kaufels Nicola, Korn Ronny, Wagner Susanne, Schink Tania, Hamm Bernd, Taupitz Matthias, Schnorr Jörg
Departments of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Invest Radiol. 2008 Jul;43(7):496-503. doi: 10.1097/RLI.0b013e31816f1be1.
To assess the contrast-enhancing effects of citrate-coated superparamagnetic iron oxide particles (VSOP-C184) in a rat liver tumor model using dynamic and delayed magnetic resonance imaging in comparison to carboxydextran-coated particles (ferucarbotran) and a hepatobiliary contrast medium (gadobenate dimeglumine).
A total of 32 male rats with liver tumors (CC-531 colorectal carcinoma) were examined at 1.5 T with a T1-weighted dynamic series (3D gradient echo sequence) and T1-weighted and T2*-weighted images (2D gradient echo sequences) before and 15 and 90 minutes after injection. VSOP-C184 was investigated at doses of 0.015, 0.045, and 0.06 mmol Fe/kg, ferucarbotran at 0.015 mmol Fe/kg, and gadobenate dimeglumine at 0.025, 0.05, and 0.1 mmol Gd/kg. Liver-tumor contrast-to-noise ratio (CNR) was calculated and statistically compared.
T1-weighted dynamic images: VSOP-C184 has significantly higher CNR values at a dose of 0,015 mmol Fe/kg than ferucarbotran at the same dose (P = 0.001). VSOP-C184 produces a significantly higher CNR at a dose of 0.045 mmol Fe/kg than gadobenate dimeglumine at a dose of 0.05 mmol Gd/kg (P = 0.019). At a dose of 0.06 mmol Fe/kg, the CNR for VSOP-C184 is significantly lower than that of gadobenate dimeglumine (0.1 mmol Gd/kg) (P = 0.005).T2-weighted delayed images: CNR values of VSOP-C184 are similar to those of ferucarbotran and are significantly higher than those of gadobenate dimeglumine (P < 0.05).
On T1-weighted magnetic resonance imaging of liver tumors VSOP-C184 produces a high contrast comparable to that of a hepatobiliary contrast medium in addition to its contrast-enhancing effect in T2-weighted imaging.
使用动态和延迟磁共振成像，在大鼠肝肿瘤模型中评估柠檬酸盐包被的超顺磁性氧化铁颗粒（VSOP-C184）的对比增强效果，并与羧基葡聚糖包被的颗粒（ferucarbotran）和一种肝胆对比剂（钆贝葡胺）进行比较。
总共32只患有肝肿瘤（CC-531结肠直肠癌）的雄性大鼠在1.5T磁场下接受检查，在注射前、注射后15分钟和90分钟分别采集T1加权动态序列（3D梯度回波序列）以及T1加权和T2*加权图像（2D梯度回波序列）。研究了VSOP-C184的剂量为0.015、0.045和0.06 mmol Fe/kg，ferucarbotran的剂量为0.015 mmol Fe/kg，钆贝葡胺的剂量为0.025、0.05和0.1 mmol Gd/kg。计算肝脏肿瘤的对比噪声比（CNR）并进行统计学比较。
T1加权动态图像：VSOP-C184在剂量为0.015 mmol Fe/kg时的CNR值显著高于相同剂量的ferucarbotran（P = 0.001）。VSOP-C184在剂量为0.045 mmol Fe/kg时产生的CNR显著高于钆贝葡胺在剂量为0.05 mmol Gd/kg时的CNR（P = 0.019）。在剂量为0.06 mmol Fe/kg时，VSOP-C184的CNR显著低于钆贝葡胺（0.1 mmol Gd/kg）（P = 0.005）。T2加权延迟图像：VSOP-C184的CNR值与ferucarbotran相似，且显著高于钆贝葡胺（P < 0.05）。
在肝脏肿瘤的T1加权磁共振成像中，VSOP-C184除了在T2加权成像中具有对比增强作用外，还能产生与肝胆对比剂相当的高对比度。
